SCHEMBL7145343

SCHEMBL7145343

Cc1ccc(-c2nc(N)nc(OC(C)c3ccccn3)c2C#N)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 13/20 0.41
ADORA2A P29274 13/20 0.41
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 5/20 0.39
MAPT P10636 4/20 0.39
HPGD P15428 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 3/20 0.39
PKM P14618 3/20 0.39
ALOX15 P16050 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 2/20 0.39
GLA P06280 1/20 0.39
ALOX12 P18054 2/20 0.37
USP2 O75604 1/20 0.37
ADORA2B P29275 3/20 0.37
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440919 0.85 ADORA2A (0.56) ADORA1ADORA2AKDM4EALDH1A1MAPT
SCHEMBL6441933 0.82 ADORA1 (0.38) ADORA1ADORA2AKDM4EALDH1A1MAPT
SCHEMBL5039926 0.80 ADORA2A (0.52) ADORA1ADORA2AKDM4EALDH1A1MAPT
SCHEMBL6446348 0.76 KDM4E (0.47) ADORA1ADORA2AKDM4EALDH1A1MAPT
SCHEMBL5131727 0.75 ADORA2A (0.52) ADORA1ADORA2AKDM4EALDH1A1MAPT
SCHEMBL5040413 0.71 ADORA2A (0.41) ADORA1ADORA2AKDM4EALDH1A1MAPT
SCHEMBL6443444 0.70 KDM4E (0.43) ADORA1ADORA2AKDM4EALDH1A1MAPT
SCHEMBL5139992 0.68 KDM4E (0.39) ADORA1ADORA2AKDM4EALDH1A1MAPT
SCHEMBL6444835 0.67 CYP1A2 (0.54) ADORA1ADORA2AKDM4EALDH1A1MAPT
SCHEMBL5044492 0.67 ADORA2A (0.60) ADORA1ADORA2AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA1 3/4885ADORA2A 1/4885KDM4E 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.